Used in the treatment of light chain (AL) amyloidosis, this antibody targets misfolded amyloid proteins in tissues. It helps the immune system clear amyloid deposits from organs such as the heart and kidneys, slowing disease progression. Clinical studies focus on improving organ function and survival in patients with systemic amyloidosis. It is administered intravenously and is part of investigational therapies aimed at reducing amyloid burden and improving quality of life.